Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia
Background As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive micr...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMJ Publishing Group
2025-07-01
|
| シリーズ: | Journal for ImmunoTherapy of Cancer |
| オンライン･アクセス: | https://jitc.bmj.com/content/13/7/e011148.full |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|